Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Pioneering work by Meisam Naeimi Kararoudi of The Ohio State University College of Medicine.
New research highlights the promise of γδ T cells as an “off-the-shelf” cancer therapy for solid tumors.
Using K562 feeder cells with membrane-bound IL-21, investigators achieved robust expansion of the Vδ1 γδ T cell subset from peripheral blood – cells with innate tumor-targeting ability independent of MHC class I.
Key findings:
- Preferential expansion of activated Vδ1 T cells
- Strong cytotoxicity against breast & ovarian cancer cells
- Sustained function in the hostile tumor microenvironment
- Even greater potency when engineered with a CAR in ovarian cancer models
This approach could overcome major hurdles in solid tumor immunotherapy and pave the way for scalable, allogeneic γδ T cell–based treatments.”
Title: IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy
Authors: Ana L. Portilloa, Misaal Mehboob, Genesis Snyder, Adnan Moinuddin, Tyrah M. Ritchie, Elizabeth Balint, Allyson E. Moore, Mohammadamin Sookhaklari, Jonathan L. Bramson, Dean A. Lee, Meisam Naeimi Kararoudi, Ali A. Ashkar
Read the Full Article.
More posts featuring Yan Leyfman.